Pancragen vs Semaglutide
A side-by-side research comparison of Pancragen and Semaglutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Pancragen | Semaglutide |
|---|---|---|
| Full name | Pancragen (Lys-Glu-Asp-Trp Pancreas Bioregulator) | Semaglutide (GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research compound (peptide bioregulator) | FDA Approved |
| Mechanism | As a signal peptide (Lys-Glu-Asp-Trp), it is proposed to regulate gene expression in pancreatic tissue, supporting normal endocrine and exocrine pancreatic function and carbohydrate metabolism. | Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1. |
| Molecular weight | ~575 Da | 4,114 Da |
| Half-life | Short (peptide) | 7 days (168 hours) |
| Bioavailability | Oral (encapsulated) or subcutaneous | High (SubQ ~89%), Moderate (oral ~1% with SNAC) |
| Typical dose | ~1-2 capsules/day or short injectable courses | 0.25 mg → titrate up to 2.4 mg |
| Frequency | Once daily | Once weekly |
| Route | Oral capsule or subcutaneous | Subcutaneous injection |
Pancragen reported benefits
- Pancreatic tissue support
- Carbohydrate metabolism support (proposed)
- Metabolic resilience
- Short course-based protocol
Semaglutide reported benefits
- Significant weight loss (15-17%)
- Improved glycemic control
- Cardiovascular risk reduction
- Reduced food cravings
- Lower HbA1c
Related comparisons
Research and educational reference only. Not medical advice.